Key Highlights
- The stock finished November 17, 2026 up 156.36% after its Phase 3 REGAL study in acute myeloid leukemia reached the primary endpoint.
- Patients on the GPS Vaccine lived a median 24.0 months overall, against 14.7 months for those on other treatments.
- Intraday the shares climbed as high as 255.2%, and after the close the company proposed a USD 150 million public offering.
- After-hours trading pushed the stock down between 10.6% and 11.2% as investors priced in dilution.
A Survival Gain in a Difficult Setting
REGAL is a Phase 3 trial testing galinpepimut-S, or GPS, in people whose acute myeloid leukemia returned after a second remission, a group with limited choices. The comparison arm received the best available treatment selected by physicians. Median overall survival reached 24.0 months on GPS versus 14.7 months in the comparison group, a gap exceeding nine months. The reported hazard ratio of roughly 0.59 implies a meaningful reduction in the risk of death. SELLAS Life Sciences (NASDAQ:SLS) said the trial met its primary endpoint, while stressing that the result is not an approval and that it intends to meet the Food and Drug Administration about the data. The agency could interpret the findings differently from the company. The disease carries a poor outlook, and patients in this setting often have few good Options after relapse. The comparison group therefore reflects the usual options doctors would pick. The result is therefore a survival signal rather than a finished regulatory story.
Shares Surged, Then Gave Back Ground on Dilution Fears
The stock vaulted 255.2% soon after the open, reaching near USD 26.53, before paring part of that move. It later traded roughly 149% higher by mid-morning and about 167% higher early in the afternoon, and it closed up 156.36%, the strongest gain on the market that day. That happened even as the S&P 500 slid to a five-month low and health care names lost 1.41%. After the bell, SELLAS Life Sciences (NASDAQ:SLS) unveiled a proposed underwritten sale of USD 150 million in common stock. Drug developers frequently raise money after positive readouts, when shares are elevated, to fund approval work and launch preparations. Existing holders face dilution, and the stock fell roughly 11% after hours, though it remained well above its pre-trial level. Volume ran many times its typical pace as retail and institutional buyers piled in. The pricing of the offering will decide how much stock new investors receive.
Pricing, FDA Dialogue and the Filing Timeline Ahead
Pricing comes first, since the final price and size will set the entry point for new investors. Attention then turns to the FDA meeting and to the complete trial results, which are likely to be presented at a medical meeting. Investors want details on adverse events, outcomes in key patient subgroups and how durable the survival advantage looks. A filing during the first half of 2027 could place an approval decision in late 2027 or 2028, depending on review timing. The company must hold enough cash to reach that stage and prepare a commercial launch, which is why the raise matters. Small biotech shares that spike on trial news often swing sharply in the days afterward as traders lock in gains. Investors also need to see whether the survival benefit holds up in full data, not just the topline result. The company's own timetable therefore carries real weight in how the stock trades next.
Where Things Stand
SELLAS Life Sciences (NASDAQ:SLS) saw a 156% jump after its Phase 3 survival result in acute myeloid leukemia, followed by an after-hours decline tied to a USD 150 million offering. Offering terms, the FDA discussion and the full data will determine the next move, and investors will weigh the cash needs against the dilution.


_11_18_2026_09_56_32_784348.jpg)



Please wait processing your request...